A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

A Phase 3, Randomized, Double-Blind Study of PF-05280586 Versus Rituximab for the First of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma

Category & Conditions:
Cancer
Medicine:
RUXIENCE™(RITUXIMAB-PVVR)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B3281006
Open Plain Language Summary Result:Click here